axitinib
axitinib: sourced relationships with 1 company · 8 clinical trials tracked · 1 FDA decision.
axitinib evidence translation
What we can confirm
1 FDA record · 8 tracked trials
What it means
What to watch
Prepared research question
How could axitinib → TEVA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) Reported 2018-08-07 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (8)
Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
Primary endpoint: Progression-free survival (PFS)
A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Primary endpoint: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Primary endpoint: Nephrectomy and radiographic progression-free survival (nrPFS)
AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.
Primary endpoint: Number of participants with adverse events leading to permanent discontinuation of study intervention
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Primary endpoint: Overall Response Rate
A Phase II, Single Arm Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy - AXAGIST
Primary endpoint: Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile
Frequently asked questions
Which companies have sourced relationships with axitinib?
axitinib has dated SEC/FDA relationship records for Teva Pharmaceutical Industries Limited.
How many clinical trials involve axitinib?
BioSniper tracks 8 clinical trials involving axitinib.
What is axitinib's latest FDA decision?
The most recent tracked FDA decision for axitinib is Tentative Approval, dated August 7, 2018.